New treatment option for partial-onset seizures: Efficacy and safety of lacosamide

Therapeutic Advances in Neurological Disorders

Volumn 3, Issue 2, 2010, Pages 77-83

  Chung, Steve S ^a  

^a Department of Neurology ^*  (United States)

Author keywords

lacosamide; new anticonvulsant; partial seizures; slow inactivation; sodium channels; Vimpat

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; HARKOSERIDE; LAMOTRIGINE; PHENYTOIN; VALPROIC ACID;

BACKACHE; CLINICAL TRIAL; CLONIC SEIZURE; DIPLOPIA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; EPILEPTIC STATE; EUROPE; FOCAL EPILEPSY; HEADACHE; HUMAN; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEIZURE; SINGLE DRUG DOSE; SOMNOLENCE; UNITED STATES;

EID: 77953397673     PISSN: 17562856     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756285609355850     Document Type: Review

References (34)

1. Andurkar, S.V., Stables, J.P. and Kohn, H. ( 1999) The anticonvulsant activities of N-benzyl 3-methoxypropionamides. Bioorg Med Chem 7: 2381-9.
2. Ben-Menachem, E. ( 2008) Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today 44: 35-40.
3. Ben-Menachem, E., Biton, V., Jatuzis, D., Abou-Khalil, B., Doty, P. and Rudd, G.D. ( 2007) Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48: 1308-17.
4. Ben-Menachem, E., Chung, S., Rudd, D., Hebert, D. and Doty, P. ( 2009) Evaluation of Lacosamide Efficacy in Subjects with Partial-Onset Seizures Across the Dose Range Used in Phase II / III Clinical Trials [abstract]. Poster Presentation, 28th International Epilepsy Congress 28 June - 2 July 2009.
5. Beydoun, A., D'Souza, J., Hebert, D. and Doty, P. ( 2009) Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 9: 33-42.
6. Beyreuther, B.K., Freitag, J., Heers, C., Krebsfanger, N., Scharfenecker, U. and Stöhr, T. ( 2007) Lacosamide: a review of preclinical properties. CNS Drug Rev 13: 21-42.
7. Bialer, M., Johannessen, S.I., Kupferberg, H.J., Levy, R.H., Perucca, E. and Tomson, T. ( 2007) Progress report on the new antiepileptic drugs: a summary of the eighth Eilat conference (EILAT VIII). Epilepsy Res 73: 1-52.
8. Bialer, M., Johannessen, S., Levy, R., Perucca, E., Tomson, T. and White, S. ( 2009) Progress report on new antiepileptic drugs: a summary of the ninth Eilat Conference (EILAT IX). Epilepsy Res 83: 1-43.
9. Biton, V., Rosenfeld, W.E., Whitesides, J., Fountain, N.B., Vaiciene, N. and Rudd, G.D. ( 2008) Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 49: 418-424.
10. Cawello, W., Kropeit, D., Schiltmeyer, B., Hammes, W. and Horstmann, R. ( 2004) Food does not affect the pharmacokinetics of SPM 927 [abstract]. Epilepsia 45: 307.
11. Centers for Disease Control and Prevention. ( 1994) Prevalence of self-reported epilepsy - United States, 1986-1990. JAMA 272: 1893.
12. Chung, S., Sperling, M., Biton, V., Krauss, G., Beaman, M. and Hebert, D. ( 2007a) Lacosamide: efficacy and safety as oral adjunctive treatment for partial-onset seizures [abstract]. Epilepsia 48: 321.
13. Chung, S., Wang, N. and Hank, N. ( 2007b) Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 16: 296-304.
14. Chung, S., Rudd, R., Hebert, D. and Doty, P. ( 2008) Evaluation of lacosamide efficacy in subjects with partial-onset seizures across the dose range used in phase II / III clinical trials [abstract]. Epilepsia 49: 426.
15. Deckers, L., Knoester, D., de Haan, G.J., Keyser, A., Renier, W.O. and Hekster, Y.A. (2003) Selection criteria for the clinical use of the newer antiepileptic drugs. CNS Drugs 17: 405-421.
16. Doty, P., Rudd, G.D., Stöhr, T. and Thomas, D. ( 2007) Lacosamide. Neurotherapeutics 4: 145-148.
17. Guevara, J., Carmona, G., Ortega, M.P. and Iglesias, A.A. ( 2005) Preliminary study on the efficacy and tolerability of newer anticonvulsants in a population of epileptic patients. Med Princ Pract 14: 31-34.
18. Halász, P., Kälviäinen, R., Mazurkiewicz-Beldzinska, M., Rosenow, F., Doty, P., Hebert, D. et al. (2009) Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 50: 443-453.
19. Horstmann, R., Bonn, R., Cawello, W., Doty, P. and Rudd, G.D. ( 2002) Basic clinical pharmacological investigations of the new antiepileptic drug SPM 927 (abstract). Epilepsia 43: 188.
20. Hovinga, C.A. ( 2003) SPM-927 (Schwarz Pharma). IDrugs 6: 479-485.
21. Kennebäck, G., Bergfeldt, L. and Tomson, T. ( 1995) Electrophysiological evaluation of the sodium-channel blocker carbamazepine in healthy human subjects. Cardiovasc Drugs Ther 9: 709-714.
22. Kennebäck, G., Bergfeldt, L., Vallin, H., Tomson, T. and Edhag, O. ( 1991) Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of the cardiac conduction system. Am Heart J 121: 1421-1429.
23. Krauss, G., Ben Menachem, E., Mameniskiene, R., Vaiciene, N., Rudd, D. and Brock, M. ( 2007) Lacosamide: safety and tolerability of adjunctive intravenous lacosamide as short-term replacement for oral lacosamide in subjects with partial-onset seizures during 30-, 15-, and 10-minute infusions. Eur J Neurol 14: 319-320.
24. Kropeit, D., Schiltmeyer, B., Cawello, W., Hammes, W. and Horstmann, R. ( 2004) Bioequivalence of short-time infusions compared to oral administration of SPM 927 (abstract). Epilepsia 45: 123.
25. Kwan, P. and Brodie, M. ( 2000) Early identification of refractory epilepsy. N Engl J Med 342: 314-319.
26. Laville, M.A., de la Gastine, B., Husson, B., Le Boisselier, R., Mosquet, B. and Coquerel, A. ( 2008) Should we care about pregabalin for elderly patients with a history of cardiac dysrhythmia? Rev Med Interne 29: 152-154.
27. Matsuo, F., Bergen, D., Faught, E., Messenheimer, J.A., Dren, A.T., Rudd, G.D. et al. (1993) Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures US Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 43: 2284-2291.
28. Perucca, E. ( 2007) Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurology 6: 793-804.
29. Rosenfeld, W., Fountaine, N., Kaubrys, G., Heinzen, L. and McShea, C. ( 2007) Lacosamide: an interim evaluation of long-term safety and efficacy as oral adjunctive therapy in subjects with partial-onset seizures (abstract). Epilepsia 48: 318.
30. Sperling, M., Rudd, D., Hebert, D. and Doty, P. ( 2008) Early onset of efficacy in the initial weeks of treatment with lacosamide: a pooled analysis of three phase II / III trials (abstract). Epilepsia 49: 457.
31. Stöhr, T., Kupferberg, H.J., Stables, J.P., Choi, D., Harris, R.H., Kohn, H. et al. (2007 a) Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 74: 147-154.
32. Stöhr, T., Shandra, P., Kashenko, O. and Shandra, A. ( 2007b) Synergism of lacosamide and first-generation and novel antiepileptic drugs in the 6 Hz seizure model in mice (abstract). Epilepsia 48: 252.
33. Thomas, D., Scharfenecker, U., Nickel, B., Doty, P., Cawello, W. and Horstmann, R. ( 2006) Low potential for drug-drug interaction of lacosamide (abstract). Epilepsia 47: 200.
34. US F.D.A. (2008) Vimpat (lacosamide) tablets and injection: US prescribing information [online]. Available from http://www.fda.gov/cder/foi/label/2008/022253lbl.pdf [Accessed 2008 Oct 30].